symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
TBPMF,0.0009,1.975795,364998,7871364,0,5.0E-4-0.1,-0.0003,Tetra Bio-Pharma Inc.,USD,,,,Other OTC,PNK,Biotechnology,https://www.tetrabiopharma.com,"Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.","Dr. Guy  Chamberland M.Sc., Master Herbal",Healthcare,CA,33,,2316 St. Joseph Boulevard,Orléans,ON,K1C 1E8,,0,https://financialmodelingprep.com/image-stock/TBPMF.png,2012-09-25,True,False,False,False,False
